

Conflict of Interest Statement

Impact of risk minimisation in patients treated with rosiglitazone-containing products

Commissioned by the European Medicines Agency

Procurement Procedure No. EMA/2010/38/CN

All investigators state that they have no conflict of interest related to this study.